ATHOS-3
2017
Angiotensin II for the Treatment of High-Output Shock
In 321 patients with catecholamine-resistant vasodilatory shock, synthetic angiotensin II improved MAP response at 3 hours compared with placebo, without proven mortality benefit.
Result
Efficacy: MAP response (≥10 mm Hg or ≥75 mm Hg) at 3 hoursOR 7.95 · P < 0.001
Below 1 favours placebo, above 1 favours synthetic angiotensin II.
- Absolute difference
- 46.5 points
- NNT
- 3
Absolute difference and NNT are derived from the event rates.
Also reported: 28-d mortality 46% vs 54% (HR 0.78; p=0.12).
- Subtopic
- Vasopressors
- Design
- Double-blind RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Khanna A, et al. N Engl J Med. 2017;377(5):419-430.doi 10.1056/NEJMoa1704154
Discussion & critique
FDA-approved 2017 for catecholamine-resistant shock; reserve for refractory cases at experienced centres.